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To evaluate the overall survival of paediatric patients with pontine gliomas treated with oral trophosphamide and etoposide.
Patients between 3 and 17 years of age with either typical diffuse pontine glioma on MRI or histologically proven anaplastic
astrocytoma/glioblastoma multiforme located in the pons, were eligible. Treatment consisted of oral trophosphamide
100 mg m
72 day
71 combined with oral etoposide at 25 mg m
72 day
71 starting simultaneously with conventional radiation.
Twenty patients were enrolled (median age 6 years, male:female=9:11). Surgical procedures included: no surgery: ﬁve, open
biopsy: three, stereotactic biopsy: six, partial resection: three, and sub-total resection: three. Histological diagnoses included
pilocytic astrocytoma: one, astrocytoma with no other speciﬁcation: three, anaplastic astrocytoma: three, glioblastoma
multiforme: eight, no histology: ﬁve. The most frequent side effects were haematologic and gastrointestinal. There was no
toxic death. The response to combined treatment in 12 evaluable patients was: complete response: 0, partial response: three,
stable disease: four, and progressive disease: ﬁve. All tumours progressed locally and all patients died. The overall median
survival was 8 months. The overall survival rates at 1 and 4 years were: 0.4 and 0.05 respectively. This was not different from
a control group of patients documented in the same population. Oral trophosphamide in combination with etoposide did not
improve survival of pontine glioma patients. The treatment was well tolerated and should be evaluated for more
chemoresponsive paediatric malignancies.
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The term ‘brain stem glioma’ had originally developed as a clin-
ical diagnosis without histological conﬁrmation because the
morbidity for surgical intervention within the pons was high
and the relevance of histological diagnoses was low. By now,
MRI morphology differentiates at least three groups of tumours
to be treated in very different ways (Barkovich et al, 1990, 1991;
Albright et al, 1993; Fischbein et al, 1996). (i) The dorsally
exophilic cervicomedullary tumours appear to beneﬁt signiﬁcantly
from surgical resection (Epstein and Constantini, 1996). (ii)
Intrinsic tectumglioma may be associated with a long history
and with neuroﬁbromatosis type I. In this case they grow very
slowly (Pollack et al, 1996; Bilaniuk et al, 1997), and a ‘wait-
and-see’ approach can provide the patient with long duration
of good quality of life. (iii) Intrinsic diffused pontine glioma,
in contrast, have a poor prognosis (Freeman and Farmer,
1998). The radiological characteristics of these tumours are:
Pontine location, hypodensity on CT, hypointensity on T1 MRI
images, hyperintensity on T2 images, no contrast enhancement,
and almost complete involvement of the cross-section of the
pons. The tumours occur in the ﬁrst decade of life after a short
history and progress quickly after diagnosis. These patients are
treated with radiotherapy, which is frequently combined with
experimental approaches. While the MRI images appear to be
highly predictive in these three groups of tumours, there are
other, less typical lesions in which imaging technologies have
not been suitable to predict the prognosis. Among those are
focal, cystic, and contrast enhancing pontine lesions. Many of
those will, on histology, turn out to be high grade glioma, but
other tumour histologies, inﬂammations, and histiocytic lesions
(Weaver et al, 1999) are possible too. To make matters more
complicated, diffuse pontine glioma can turn into cystic or
focally contrast enhancing lesions as a part of their natural
history (Nelson et al, 1994).
On histology, brain stem gliomas are predominately astrocytic
tumours. In other locations and age groups, tumour gradings such
as the WHO classiﬁcation, have proven to be of high prognostic
value. This even includes adult patients with brain stem glioma
(Selvapandian et al, 1999). But there appears to be a biologically
different tumour entity in the paediatric age group of pontine glio-
ma. In this age group, histological grading has not been of
prognostic signiﬁcance (Steck and Friedman, 1995; Selvapandian
et al, 1999; Kaplan et al, 1996). Two distinct age peaks in the inci-
dence of brain stem glioma (ﬁrst decade and third to fourth decade
of life) support this hypothesis of biologically different tumours
(Tokuriki et al, 1986; Steck and Friedman, 1995; Selvapandian et
al, 1999). Diffuse pontine glioma in children remains almost
unique as a diagnosis, in which radiation and intensive chemother-
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Radiotherapy frequently results in clinical improvement of
diffuse pontine glioma and approximately doubles the median
survival to 1 year (Freeman and Farmer 1998). Increasing the
intensity of radiotherapy by hyperfractionation (Packer et al,
1994, 1996), and acceleration (Lewis et al, 1997) did not increase
the survival further and the sequelae suggest caution with this
approach (Freeman et al, 1996). Chemotherapy did not add to
the therapeutical success of radiation treatment. In contrast to
the success in medulloblastoma, the addition of CCNU, vincristine,
and prednisone did not improve survival in a prospective rando-
mised trial (Jenkin et al, 1987). Intensifying nitrosurea treatment
with stem cell rescue (Bouffet et al, 1997) or the use of other bone
marrow transplant agents such as thiotepa, VP16, busulphan, and
carboplatin (Dunkel et al, 1998; Kalifa et al, 1999) did not improve
survival either. Presently, novel agents such as topotecan (Kadota et
al, 1999), temozolomide (Estlin et al, 1998) and simultaneous
chemotherapy with radiation (Allen et al, 1999) are studied.
In 1988 the Society of Pediatric Oncology and Hematology
in the Germanic language group (GPOH) started to document
(HIT-DOC) paediatric brain tumour patients who are not
enrolled in other clinical studies. For patients with diffuse
pontine glioma and glioblastoma multiforme, a series of phase
I/II treatment trials was activated in 1995 (Wolff et al,
1996a). This report describes the ﬁnal data of the ﬁrst of these
trials (HIT-GBM-A) for pontine glioma. In this study, patients
were treated with conventional radiotherapy and oral
chemotherapy with trophosphamide 100 mg m
72, and etoposide
25 mg m
72 daily
71 (Wolff et al, 1996b). The results of malig-
nant glioma in location outside of the brain stem has been
reported elsewhere (Wolff et al, 2000).
PATIENTS OF THE TREATMENT GROUP
This treatment protocol was open for patients between 3 and 17
years of age, with newly diagnosed pontine tumours. The diagnosis
had to be conﬁrmed by at least one of two reference centres. Typi-
cal diffuse pontine gliomas were enrolled based on the
characteristic MRI morphology in combination with a history of
less than 6 months. The MRI morphology had to be conﬁrmed
by the Neuroradiology Reference Center. Patients with atypical
radiomorphology required a histological conﬁrmation. In those
patients, only anaplastic astrocytoma grade III (WHO) and glio-
blastoma multiforme were enrolled. The histology had to be
conﬁrmed by the Neuropathology Reference Center. The study
enrolled patients mainly between July 1995 and April 1997, by
which time it was substituted by the following protocol (‘HIT-
GBM-B’). However, two patients were enrolled after the planned
study closure and were not excluded from this analysis.
Twenty patients with pontine tumours were enrolled in the
treatment study HIT-GBM-A. The male:female ratio was 9:11,
the median age was 6 years (Table 1). The family history and
previous history of the patients were unremarkable in all. All
tumours were located in the pons, there was no dorsal exophytic
tumour in this group. Surgery was done in 15 of the 20 patients
(Table 1). Only nine of these patients would have required histol-
ogy for enrollment because the tumours were contrast enhancing,
the other six patients who had undergone surgery had typical
radiomorphology. Surgical procedures included stereotactic biopsy
in six, open biopsy in three, partial resection in three, and sub-total
resection in three patients. Histology included: three astrocytomas
with no other speciﬁcations WHO grade II, one pilocytic astrocy-
toma, three anaplastic astrocytomas, and eight glioblastoma
multiformes (Table 1). The tumours with grade I and grade II
histology were enrolled based on the MRI morphology of diffuse
pontine glioma.
PATIENTS OF THE CONTROL GROUP
The documentation study ‘HIT-DOC’ allowed retrospective enroll-
ment. In contrast to the treatment study, a Neuroradiology
Reference Centre did not exist for the patients of the documenta-
tion study. In order to compile a control group compatible with
the treatment group, the following inclusion criteria were used:
location=‘pons’, age=3–17 years, and radiation=‘yes’. Exclusion
criteria were: (i) double-documentation on the treatment cohort,
and (ii) patients enrolled in one of the later treatment protocols
(HITGBM-B, and -C). This left 26 patients eligible for the control
group. As expected, the year of diagnosis was much more wide-
spread, ranging from 1983 to 1998 (Table 1). The age at
diagnosis, however, was quite similar to the treatment group
(median age: 7 years, range 3–17, Table 1). The male:female ratio
was 12:14. Surgery was performed in 21 of these patients and was
classiﬁed as: stereotactic biopsy: 14, open biopsy: ﬁve, partial
resection: one, sub-total resection: one (Table 1). Histological
results were diagnostic in 19 patients: Two ﬁbrillary astrocytomas,
three astrocytomas with no other speciﬁcation WHO grade II,
eight anaplastic astrocytomas, and six glioblastoma multiformes
(Table 1).
POSTOPERATIVE TREATMENTS
The study protocol included up front standard fractionated radio-
therapy to the tumour region plus 2 cm margins in 30 fractions of
1.8 Gy resulting in a total dose of 54 Gy, given over a period of 6
weeks with one radiation on 5 of 7 days per week. This was
completed in 18 of the 20 patients. A 5-year-old girl received only
50 Gy after a partial resection of a glioblastoma multiforme, an 8-
year-old boy with stereotactically biopsied pilocytic astrocytoma
received 56 Gy.
The chemotherapy included trophosphamide 100 mg m
72 day
71
per os, and etoposide 25 mg m
72 day
71 per os daily for 21 days
followed by a week of rest, after which the next cycle started.
Chemotherapy was started simultaneously with radiation as soon
as the diagnosis was conﬁrmed and was planned for a period of 1
year or 13 cycles. All patients of the treatment group started this
protocol. It was discontinued when the tumours progressed, and it
was extended after completing the 13 cycles in a few patients by
parents’/physicians’ choice. This resulted in a mean number of cycles
of 7.2 (standard deviation 5.4, median 6.5, range 1–19).
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Table 1 Patient’s characteristics
Control group Study group
Age at diagnosis:
range 3–15 3–15
median 7 6
Gender:
male:female 12:14 9:11
Year of diagnosis:
range 1983–1998 1995–1998
median 1993 1996
Surgery:
No surgery 5 5
Open biopsy 5 3
Stereotactic biopsy 14 6
Partial resection 1 3
Subtotal resection 1 3
Grading (WHO):
I/II/III/IV/unknown: 0/5/8/6/7 1/3/3/8/5
The year of diagnosis was different between the two groups (Wilcoxon test
P50.05), differences of the other parameters were not statistically signiﬁcant.
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neous, as it was not a treatment protocol but a documentation
study, summarising, what was done by different institutions. By
deﬁnition, all patients had radiotherapy. Five patients had stereotac-
tic seed implantations, while three of them had additional external
radiotherapy. The external radiotherapy doses varied between 15
and 64.8 Gy (mean 46.6, standard deviation 14.5, median 54 Gy).
In addition to the radiation, chemotherapy was given in 16 patients.
Three patients received carboplatinum/vincristine, one patient was
treated according to the CCNU/vincristine/cisplatinum chemother-
apy protocol (Packer et al, 1996, 1999), four patients were treated
according to an intense chemotherapeutic protocol designed for
medulloblastoma, using cisplatinum, Ara-C, etoposide, iphospha-
mide, and high dose methotrexate (Kuhl et al, 1998), and six
patients received various types of other institutional chemothera-
peutic protocols. Ten patients did not receive any chemotherapy,
and chemotherapy was not documented in one patient.
RESULTS
Oral chemotherapy with trophosphamide/VP16 was well tolerated.
There were no treatment-related deaths. Less severe side effects
were not the primary objective of this study, and the documenta-
tion was insufﬁcient in four patients. Of the remaining 16 patients,
one had no side effects. Nausea was reported in eight patients, and
vomiting in ﬁve of those. Haematological side effects were reported
in 13 patients (NIH grade II: eight, grade III: two, grade IV: three).
Of those, one patient developed fever and neutropenia and
required admission for antibiotic treatment. Rare side effects
included increase of liver enzymes (NIH grade III), abdominal
pain, dysuria (NIH grade II), and haematuria (NIH grade I) in
one patient each. Response to treatment could be evaluated in 12
patients. The response rates were: complete response: 0, partial
response: three, stable disease: four, progressive disease: ﬁve. All
patients eventually died from local tumour progression. Time to
progression was deﬁned as time interval between diagnosis and
either tumour growth seen in neuroimaging (425% product of
two perpendicular diameters) or death of disease, whatever came
ﬁrst. Using this deﬁnition, the median time to progression was
5.9 months (standard error: 1.7 months, 95% Conﬁdence Interval
(CI): 2.6–9.1), the mean time to progression was 9.6 months
(standard error: 1.9, 95%CI: 5.8–13.4). The median overall survi-
val time was 8 months (standard error 1.6, 95%CI: 4.9–11), the
mean overall survival time was 13.8 months (+2.8, 95%CI: 8.4–
19.2). The overall survival rates (and standard errors) at 1, 2, 3,
4, and 5 years were: 0.4 (+.11), 0.15 (+.08), 0.05 (+.05), 0.05
(+.05), and 0 (+0), (Figure 1).
The control group from the documentation study (HIT-DOC)
had comparable survival rates with a median event free survival
time of 7 months (standard error 2.8, 95%CI 1.7–12.2). The
median overall survival time of the control group was 11 months
(standard error 1.6, 95%CI: 7.8–14.2). The 1 and 2 year overall
survival rates were 0.40 (+0.11 standard error), and 0 (+0).
The survival curves (Figure 1) of the two groups were superim-
poseable up to 1 year of follow up. After that, the VP16/
trophosphamide group seems to have a slightly longer overall
survival. However, this was not signiﬁcant (P=0.7 for overall survi-
val, P=0.75 for progression-free survival, deﬁnitions identical in
both patient groups, log rank tests). Multivariate analyses done
with the Cox regression model, with both overall and progression
free survival as endpoints, conﬁrmed the lack of a signiﬁcant differ-
ence between the two groups.
DISCUSSION
Trophosphamide is an oxazaphosphorine, which is more lipid
soluble as compared to cyclophosphamide and iphosphamide. This
results in better intestinal reabsorption and allows oral treatment.
Hepatic activation produces 4-hydroxy metabolites, including 4-
hydroxy-iphosphamid (Boos et al, 1993). While other oxazapho-
sphorines are widely used in the treatment of astrocytic tumours
(Freeman and Perilongo, 1999), trophosphamide (Wagner et al,
1997) had not yet been investigated in brain tumours to our know-
ledge. It has shown efﬁcacy in soft tissue sarcoma (Blomqvist et al,
1995; Kollmannsberger et al, 1999), malignant lymphoma (Helsing,
1997), and non-Hodgkin lymphoma (Salminen et al, 1997). Nega-
tive results were published in colorectal cancer (Strumberg et al,
1997) and pancreatic cancer (Schmidt-Sandte et al, 1999).
Etoposide (VP16) is a topoisomerase II inhibitor from the group
of epipodophyllotoxins. It is widely used in paediatric brain
tumour treatment and given in many different schedules. Oral
continuous chemotherapy has recently shown activity in glioma
(Chamberlain, 1997; Needle et al, 1997). Combining DNA alkylat-
ing agents with topoisomerase inhibitors is frequent practice and
partially based on the rationale, that the topoisomerases are neces-
sary for DNA repair mechanisms activated after DNA alkylation.
Unfortunately, this effect also seems to enhance haematological
side effects, which increase upon combining the two agents. There-
fore, in combinations, drug dosages need to be reduced.
Treatment intensiﬁcation has increased cure rates in a number
of paediatric malignancies. In phase II studies, normally one dose
level below the maximal tolerated dose is used. In view of the short
remaining lifetime of patients with pontine glioma, the tropho-
sphamide/VP16 treatment intensity was picked differently
(Tillmann et al, 1998). The long term schedule was chosen similar
to leukaemia maintenance chemotherapy and antiangiogenic
chemotherapeutic approaches. The plan with respect to treatment
intensity was to avoid the need for inpatient treatment, and this
goal was achieved in all but one patient, who was admitted for
fever and neutropenia. Less severe side effects such as nausea/
vomiting, and leukopenia occurred in all but one patient, indicat-
ing that the dose was not too low. Judged by this measure, the
chemotherapeutic dosing was adequate, and can be recommended
for phase II studies, when the same intensity is desired in the treat-
ment of other paediatric malignancies. Higher doses are obviously
possible, but will likely increase the number of inpatient admis-
sions for supportive care.
Diffuse and malignant pontine glioma in childhood remains a
challenge of paediatric cancer care. Our treatment did not change
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Figure 1 Overall survival of pontine glioma patients treated with etopo-
side and trofosfamide (VP16/TRO, n=20), compared to patients with other
treatments (controls, n=26). Six patients of the control group were lost to
follow up (six censored). The difference between the two groups is not
statistically signiﬁcant (log rank test P=0.7).
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survival curve could suggest a beneﬁt by increasing the remaining
life span for about 20% of the patients. However, this is not statis-
tically different from the control group. Since this was not a formal
randomised phase III study, there is some risk that an existing
minor beneﬁt may not be detected. In addition, the control group
is somewhat inhomogeneous since some patients received
chemotherapy far more intense than the oral trophosphamide/
VP16, which was tested here. However, the population available
for registration of patients was not large enough for a phase III
study. The prospective cohort comparison study design comparing
each protocol with the previous cohorts, was the best that could be
done in that situation. Trophosphamide/VP16 was the ﬁrst of these
protocols, the evaluation of which has to rely on a comparison
with data collected in another setting. The German documentation
study (HIT-DOC) was the most appropriate set of data for this,
since they were collected in the same population and partially
covered the same period for years of diagnosis. In this comparison,
no signiﬁcant difference was detected between the two groups.
Response to chemotherapy is a difﬁcult endpoint for a
chemotherapy study with paediatric pontine glioma. Up to now,
no chemotherapeutic protocol has matched the results of radiation.
Delaying radiation in order to collect clean data for response to
chemotherapy, had been controversially discussed and would have
reduced the number of participating centres. The concept might
be more suitable for a disease, which does not progress as fast as
pontine glioma. Starting chemotherapy simultaneously with radia-
tion will give response rates to the combined treatment. These
data are of limited value unless they are compared to response rates
of radiation only. In this cohort, the response of 12 patients was: 0/3/
4/5 for complete response/partial response/stable disease/progressive
disease. When comparing this to literature data from other popula-
tions, there does not appear to be an improvement (Packer et al,
1994; Lewis et al, 1997). Since survival times were not prolonged
either (Figure 1), these data suggest that the oral chemotherapy with
TRO/VP16 did not add to the antitumour effect of radiotherapy.
The experience of this study with pontine glioma patients is
negative with respect to antitumour effects. This does not preclude
antitumour effectiveness in other malignancies, since all
chemotherapeutic protocols tested in pontine gliomas up to now
have failed, even when they are effective in more chemoresponsive
tumours. This combination can safely be given to paediatric
patients as palliative chemotherapy in other settings, since it was
easy to monitor, side effects were mild, and since the treatment
intensity can easily be adjusted on an individual basis.
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